Biopharma Group Adds Global Members, Maintains Legal Safeguards
Published Date: 1/20/2026
Notice
Summary
The Biopharmaceutical Manufacturing Preparedness Consortium (BIOMAP-CONSORTIUM) just added a bunch of new members from the U.S. and around the world to boost their teamwork on biopharmaceutical research. This update keeps their special legal protections against big antitrust lawsuits in place, helping them focus on innovation without costly legal distractions. If you’re part of this field, watch for more membership updates coming soon!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Antitrust Damage Limit Extended
If you are a member of the Biopharmaceutical Manufacturing Preparedness Consortium (BIOMAP-CONSORTIUM), the consortium filed notifications on July 24, 2025 that extend the Act's protection limiting antitrust plaintiffs' recovery to actual damages under specified circumstances. That means members to this venture are covered by the Act's narrower damage exposure while participating in the group's research activities.
Multiple New Members Added
BIOMAP-CONSORTIUM added a group of new parties to the venture, including named U.S. and international companies, universities, and research firms (for example: Public Health Vaccines LLC, International AIDS Vaccine Initiative, Matisse Pharmaceuticals B.V., Kansas State University, and others). Those named organizations are now parties to the consortium as of the July 24, 2025 notification.
Membership Open; More Notices Planned
The notice states that membership in BIOMAP-CONSORTIUM remains open and that the consortium intends to file additional written notifications disclosing future membership changes. That means other organizations in this field may join later and receive the same statutory protections once added and notified.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19100, United States of America, et al. v. RealPage, Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government is stopping Pinnacle Property Management from using RealPage’s pricing software that shares sensitive info with landlords, which broke competition rules. Pinnacle must also set up new rules to keep things fair and help the government watch over this. People have 60 days to share their thoughts before the court makes it official.
2026-18136, United States v. KKR & Co. Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government caught KKR & Co. Inc. for not properly reporting important business deals before they happened—16 times! Now, KKR has to pay a huge $250 million fine within 30 days to settle the case. This action helps keep big business honest and fair for everyone.
2026-16850, United States of America, et al. v. CRH PLC, et al. Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Tennessee are stopping APAC-Tennessee from buying Standard Construction Group because it could hurt competition. To fix this, both companies must sell two key facilities in Memphis and Millington, Tennessee. People have 60 days to share their thoughts before the deal is finalized, keeping the market fair and open.
2026-16112, United States et al. v. Cal-Maine Foods, Inc. et al.; Proposed Final Judgment and Competitive Impact Statement
2026-14903, United States, et al. v. OhioHealth Corporation; Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Ohio are taking on OhioHealth Corporation for using sneaky contract rules that stop insurers from offering cheaper health plans. OhioHealth must now remove these rules and promise not to use them again, helping more budget-friendly options reach patients. People have 60 days to share their thoughts before the court makes it official.
2026-14935, United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
The U.S. government says Edwards LifeSciences broke the rules when it bought JC Medical from Genesis MedTech. Edwards must pay $10 million, Genesis pays $2 million, and Edwards has to get approval before buying any company working on special heart valve devices in the U.S. This keeps the market fair and protects competition in heart health tech.
Previous / Next Documents
Previous: 2026-00951, Notice Pursuant to the National Cooperative Research and Production Act of 1993-Pistoia Alliance, Inc.
The Pistoia Alliance, a group of companies working together on research, just updated its membership by adding eight new members and saying goodbye to six others. This change helps keep their special legal protections against big lawsuits in place. No money or project plans changed, and they’ll keep sharing updates as new members join or leave.
Next: 2026-00955, Certain Nasal Devices and Components Thereof; Notice of Commission's Request for Written Submissions on Remedy, the Public Interest, and Bonding
The U.S. International Trade Commission is asking for written feedback on how to handle a patent dispute involving certain nasal devices and their parts. This affects companies in the U.S. and China, with possible changes to imports and sales that could impact money and business soon. If you’re involved or interested, now’s the time to speak up before decisions are made!